Eli Lilly Shrugs Off Viking Therapeutics' Weight Loss Win
💡 Key Takeaway
Viking Therapeutics' impressive VK2735 maintenance data poses a long-term threat, but Eli Lilly's own robust maintenance strategy and late-stage pipeline keep it the safer bet for most investors.
Viking Therapeutics Delivers Strong Clinical Results
Viking Therapeutics, a clinical-stage biotech, released impressive results from a mid-stage study of its leading obesity candidate, VK2735. The trial enrolled about 180 patients who received either various doses of subcutaneous VK2735 or a placebo. After 21 weeks of weekly dosing, patients on VK2735 lost between 16% and 19% of their body weight, which is competitive with existing therapies.
What really stood out was the maintenance phase. After the initial 21 weeks, patients switched to less frequent dosing—either every other week or monthly—for another 12 weeks. Those on the every-other-week schedule maintained up to 97% of their weight loss, while the monthly group maintained up to 90%. In contrast, the placebo group maintained only 61% of their weight loss.
These results suggest VK2735 could offer a convenient maintenance option for patients who have already lost weight on other drugs, including Eli Lilly's Zepbound. Viking also has an oral formulation of VK2735 in clinical trials, further expanding its potential.
Despite this promising data, Eli Lilly's stock barely budged, closing down just 0.01%. The market seems unfazed by the competitive threat, at least for now.
Why Eli Lilly Investors Aren't Worried
There are several reasons why Eli Lilly's stock didn't react to Viking's news. First, Viking's study was a proof-of-concept trial, not a large, late-stage pivotal study. The results, while strong, need confirmation in bigger and longer trials before they can be considered definitive.
Second, the trial only tested VK2735 as a maintenance therapy in patients who had already lost weight on VK2735 itself, not on a competitor's drug like Zepbound. It's unclear whether patients who lose weight on Zepbound would experience the same maintenance benefits if they switch to VK2735.
Third, and most importantly, Eli Lilly has its own comprehensive maintenance strategy. The company has tested its oral weight loss drug, Foundayo, as a maintenance therapy for patients who lost weight on Zepbound or Wegovy. In a Phase 3 study, patients initially on Wegovy regained only about 0.9 kg after 52 weeks of daily oral Foundayo, while those initially on Zepbound regained about 5 kg. Eli Lilly also showed that switching to a lower dose of Zepbound after significant weight loss helped patients keep most of the weight off.
These factors, combined with Eli Lilly's strong financial performance and deep pipeline, explain why the market isn't overly concerned about Viking's recent clinical win. The weight loss market is enormous and growing, and Eli Lilly is well-positioned to maintain its leadership.
Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.
Bobby Insight
Eli Lilly is a core holding for long-term investors seeking exposure to the weight loss market, while Viking Therapeutics is a speculative buy for those with high risk tolerance.
Eli Lilly's established market leadership, robust pipeline, and financial strength make it a safer bet. Viking's promising data could lead to significant upside if its drug succeeds in late-stage trials, but the risk of failure is substantial. The market's reaction suggests that Eli Lilly's competitive position remains strong.
What This Means for Me
